Research
Hormonal
GLP-1 receptor agonists achieve clinically significant weight loss of 15–22.5% total body weight.
GLP-1 RAs can be considered effective options for achieving significant weight loss in obesity management.
StrongSupportsmedium confidence
These medications achieve clinically significant weight loss of 15–22.5% total body weight.
Why this rating
The claim is based on a synthesis of current evidence presented in the review.
Source
Obesity management medications for the surgeon
Matthew Harris et al. · Frontline Gastroenterology · 2026
DOI 10.1136/flgastro-2025-103307
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →